🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Systemic Lupus Erythematosus, SLE
Clinical trial register · China

Systemic Lupus Erythematosus, SLE Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 12 Shanghai 9 Wuhan 7 Shenzhen 5 Guangzhou 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology5 China Immunotech (Beijing) Biotechnology Co., Ltd.4 Beijing GoBroad Hospital3 Bioray Laboratories2 Novartis Pharmaceuticals1
Site location
Beijing12 Shanghai9 Wuhan7 Shenzhen5 Guangzhou5
All 32 locations
Target enrolment
to

Systemic Lupus Erythematosus, SLE trials in China

45 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155Systemic Lupus Erythematosus (SLE)
DrugESG206
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Shenzhen, Zhongshan, Guilin, Liupanshui, Handan, Shijiazhuang, Changde, Changsha
2026-09-01
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986Systemic Lupus Erythematosus (SLE)
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
120
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guilin, Nanning
2026-03-26
Recruiting
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
NCT07490041Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE), Connective Tissue Disease-associated Interstitial Lung Disease
The Children's Hospital of Zhejiang University School of Medicine
Phase EARLY_PHASE1
36
Hangzhou
2026-03-19
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
2026-03-10
Not yet open
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
NCT07439029Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis, Idiopathic Inflammatory Myopathies (IIMs), ANCA Associated Vasculitis (AAV)
DrugYTS109 cell
Children's Hospital of Fudan University
Phase 1
12
Shanghai
2026-03
Recruiting
Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus
NCT07425730Systemic Lupus Erythematosus (SLE)
Shanghai Jiao Tong University School of Medicine
Observational
60
Shanghai
2026-02-01
Recruiting
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
NCT07331272Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)
Nanjing Legend Biotech Co.
Phase 1
38
Bengbu, Guangzhou, Changsha, Xuzhou, Nanchang
2026-01-29
Recruiting
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
NCT07413341Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy
Therorna
Phase 1
12
Shanghai
2026-01-22
Recruiting
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
NCT07339332Systemic Lupus Erythematosus (SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
12
Wuhan
2026-01-16
Not yet open
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugHC022
HC Biopharma Inc.
Phase 1
32
Beijing
2025-12-30
Recruiting
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07444307Systemic Lupus Erythematosus (SLE)
Hangzhou Qihan Biotech Co., Ltd.
Phase 1
18
Hefei, Wuhan, Beijing
2025-12-15
Recruiting
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
NCT07340463Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
DrugsBelimumab·Mycophenolate Mofetil·Telitacicept
Nanjing University School of Medicine
Phase 2
50
Nanjing
2025-12-08
Recruiting
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
NCT07236801Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy
DrugYTS109 cell
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Xuzhou
2025-11-13
Recruiting
F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus
NCT07829614Systemic Lupus Erythematosus (SLE)
DrugF182112
Shandong New Time Pharmaceutical Co., LTD
Phase 1
64
Shanghai
2025-10-30
Not yet open
A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
NCT06900764Systemic Lupus Erythematosus (SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
24
Wuhan
2025-10-10
Recruiting
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
NCT07185269Systemic Lupus Erythematosus (SLE)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
198
Beijing
2025-09-24
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
DrugCizutamig
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
NCT07174843Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP), Systemic Lupus Erythematosus(SLE)
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1
20
Shanghai
2025-09
Recruiting
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835Systemic Lupus Erythematosus (SLE)
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
189
Beijing
2025-08-25
Recruiting
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
NCT07123519Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Tianjin
2025-08-13
Recruiting
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07104721Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
DrugYTS109 cell
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Hefei
2025-08-04
Recruiting
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
NCT07031713Systemic Lupus Erythematosus (SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
12
Wuhan
2025-07-11
Recruiting
Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells
NCT07041801Systemic Lupus Erythematosus (SLE)
DrugMedium
Shenzhen Beike Bio-Technology Co., Ltd.
Phase 1/2
58
Shenzhen
2025-06-28
Recruiting
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
NCT06892145Systemic Lupus Erythematosus (SLE), Refractory
DrugMC-1-50
Chongqing Precision Biotech Co., Ltd
Phase 1
12
Hefei, Hangzhou
2025-06-12
Not yet open
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus
NCT06945068Systemic Lupus Erythematosus (SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
19
Wuhan
2025-06
Recruiting
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT06980597Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
Beijing GoBroad Hospital
Phase 1
44
Beijing
2025-06
Recruiting
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978647Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
DrugYTS109 cell
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
12
Beijing
2025-05-19
Recruiting
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NCT06902844Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
DrugEquecabtagene Autoleucel
Tongji Hospital
Not applicable
6
Wuhan
2025-04-05
Recruiting
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
NCT06946485Systemic Lupus Erythematosus (SLE)
DrugCHT101
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase EARLY_PHASE1
15
Nanjing
2025-04-02
Recruiting
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
NCT06822881Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Beijing GoBroad Hospital
Phase 1
27
Beijing
2025-02-20
Recruiting
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
NCT06653556Systemic Lupus Erythematosus (SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
34
Wuhan
2025-01-08
By invitation
Study on Early Visual Dysfunction in Patients With Systemic Lupus Erythematosus
NCT07679776Systemic Lupus Erythematosus (SLE), Visual Function
The First Affiliated Hospital of Anhui Medical University
Observational
100
Hefei
2025-01-01
Recruiting
Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
NCT06789107Systemic Lupus Erythematosus (SLE), Children, Blinatumomab
DrugBlinatumomab
Mao Jianhua
Phase 1
6
Hangzhou
2024-12-08
Recruiting
Safety Study of CC312 in Autoimmune Disease Patients
NCT06888960Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
DrugCC312
CytoCares Inc
Phase EARLY_PHASE1
18
Tianjin
2024-11-08
Recruiting
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
NCT06314282Systemic Lupus Erythematosus (SLE)
AstraZeneca
Observational
200
Guangzhou, Hong Kong, Shenzhen, Zhongshan, Zhuhai
2024-10-22
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Beijing GoBroad Hospital
Phase 1/2
18
Beijing
2024-10-17
Active, closed
Immune Cell Subsets in SLE Patients Treated with Telitacicept
NCT06677801Systemic Lupus Erythematosus (SLE)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
50
Hangzhou
2024-10-11
Recruiting
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
NCT06675422Systemic Lupus Erythematosus (SLE)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2
20
Kunming
2024-10-09
Active, closed
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
NCT06335979Systemic Lupus Erythematosus, SLE
DrugPIT565
Novartis Pharmaceuticals
Phase 1
54
Beijing
2024-10-08
Not yet open
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
NCT06420154Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
First Affiliated Hospital of Wenzhou Medical University
Phase EARLY_PHASE1
9
Wenzhou
2024-05-27
Recruiting
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT06249438Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS)
RenJi Hospital
Phase 1
30
Shanghai
2024-03-20
Recruiting
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
NCT06010472Systemic Lupus Erythematosus (SLE)
Changhai Hospital
Phase EARLY_PHASE1
36
Shanghai
2023-08-20
Recruiting
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
NCT05988216Systemic Lupus Erythematosus (SLE)
DrugBRL-301
Bioray Laboratories
Not applicable
12
Hangzhou
2023-08-14
By invitation
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
DrugBRL-301
Bioray Laboratories
Not applicable
15
Shanghai
2023-05-17
By invitation
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05352919Systemic Lupus Erythematosus (SLE)
DrugLitifilimab
Biogen
Phase 3
864
Beijing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Haikou, Shijiazhuang, Changsha
2022-06-10
Rows per page Showing 1–45 of 45
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/systemic-lupus-erythematosus-sle

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 45 of those studies listing the condition Systemic Lupus Erythematosus, SLE.

How many Systemic Lupus Erythematosus, SLE trials are recruiting in China?

34 of the 45 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 2 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Systemic Lupus Erythematosus, SLE), 45 studies
PhaseStudiesRecruitingShare
Phase 1191542.2%
Phase EARLY_PHASE18717.8%
Phase 1/25511.1%
Not applicable428.9%
Observational326.7%
Phase 2326.7%
Phase 3214.4%
Phase 4102.2%

Most active sponsors

Lead sponsors with the most studies (Systemic Lupus Erythematosus, SLE)
Lead sponsorStudiesRecruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology53
China Immunotech (Beijing) Biotechnology Co., Ltd.44
Beijing GoBroad Hospital33
Bioray Laboratories21
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China11
AstraZeneca11
Biogen10
Candid Therapeutics11
Changhai Hospital11
Children's Hospital of Fudan University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.